GlobeNewswire
Subversive Acquisition LP Announces Extension of Permitted Timeline for Completion of Its Qualifying Transaction
TORONTO, April 08, 2021 (GLOBE NEWSWIRE) — SUBVERSIVE ACQUISITION LP (TSX: SVX.U, NEO: SVX.U, OTCQX: SBVRF) (“SVX”) announced today that the date by which SVX has to consummate its qualifying transaction is extended to August 31, 2021 (the “Extension”). On January 26, 2021, SVX announced its qualifying transaction to combine with InterCure Ltd. (dba Canndoc) (TASE: INCR), Israel’s leading cannabis company (the “Business Combination”). Canndoc, a wholly owned subsidiary of InterCure Ltd., is Israel’s largest licensed cannabis producer. On April 6, 2021, unitholders approved the Business Combination, with over 89.36% of the votes cast in favour of the plan of arrangement (the “Plan of Arrangement”) pursuant to which the Business Combination will be effected. On April 7, 2021, SVX obtained the final order of the British Columbia Supreme Court approving the Plan of Arrangement. Closing of the Business Combination is expected to occur as soon as practicable after the outstanding conditions to closing are met. In connection with the Extension, 13.8 million restricted voting units of SVX have been deposited for redemption. SVX will redeem these units at a redemption price of approximately $10.04 per unit. About SVX Subversive Acquisition LP is a limited partnership established under the Limited Partnerships Act (Ontario) formed for the purpose of effecting, directly or indirectly, an acquisition of one or more businesses or assets, by way of a merger, amalgamation, arrangement, equity exchange, asset acquisition, equity purchase, reorganization, or any other similar business combination involving SVX that will qualify as its qualifying transaction for the purposes of the rules of the TSX and Neo Exchange Inc. SVX is a special purpose acquisition corporation for the purposes of the rules of the TSX and Neo Exchange Inc. For more information, visit https://www.subversivecapital.com/svx. About Subversive Capital Subversive Capital is a leading investment firm dedicated to investing in radical companies whose core missions subvert the status quo. With almost a decade of experience in the global cannabis industry, Subversive Capital has led investments in some of the most successful transactions in the industry including the recent launch and closing transaction of Subversive Capital Acquisition Corp. to form The Parent Company (TPCO Holding Corp.) currently traded on the Neo Exchange and OTCQX. For more information, visit www.subversivecapital.com. About InterCure (dba Canndoc) InterCure (TASE: INCR) is the first public company on the Tel Aviv Stock Exchange to hold a valid and permanent license for the medical cannabis value chain through its 100% ownership in Canndoc. Canndoc is a GMP medical cannabis producer. Licensed by the Israeli Ministry of Health since 2008, Canndoc is a leading pioneer in the research, cultivation, production, and distribution of pharma-grade cannabis-based products to patients, hospitals, pharmacies, research and governmental organizations. Through its strategic exclusive collaboration with world leaders, distribution agreement with SLE (100% owned by Teva Pharmaceutical Industry) and long-term sales agreements, Canndoc is well-positioned as a leading and significant player in pharma-grade medical cannabis in Israel, Europe and the United Kingdom. For more information, visit: http://www.canndoc.com. Forward‐Looking Statements This press release may contain forward-looking information within the meaning of applicable securities legislation which reflects SVX’s current expectations regarding future events. The words “will”, “expects”, “intends” and similar expressions are often intended to identify forward-looking information, although not all forward-looking information contains these identifying words. Specific forward-looking information contained in this press release includes, but is not limited to: statements concerning the completion and proposed terms of, and matters relating to, the Business Combination, statements concerning the redemption price, the timing of the redemption and unexpected events generally. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond SVX’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to: failure to complete the Qualifying Transaction, inability to obtain requisite regulatory approvals, changes in general economic, business and political conditions, changes in applicable laws, the U.S. and Canadian regulatory landscapes and enforcement related to cannabis, changes in public opinion and perception of the cannabis industry, reliance on the expertise and judgment of senior management, as well as the factors discussed under the heading “Risk Factors” in the Prospectus, which is available on SEDAR at www.sedar.com. SVX undertakes no obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. FOR FURTHER INFORMATION PLEASE CONTACT: INVESTORS:SVXinvestor@subversivecapital.com MEDIA: Subversive Acquisition LPBerrin NoorataBerrin@subversivecapital.com InterCure Ltd.Adam Haliva, Global Investor Relationsadam@canndoc-pharma.com, (972) 54-646-8778
Be the first to comment